NextCure, Inc. (NXTC)

NextCure Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	0	0	0	22.38	6.35
Revenue Growth (YoY)	-	-	-	252.58%	-
Gross Profit	0	0	0	22.38	6.35
Selling, General & Admin	19.71	21.71	20.57	17.05	9.61
Research & Development	47.93	54.2	50.19	46.55	34.22
Operating Expenses	67.64	75.91	70.77	63.6	43.83
Operating Income	-67.64	-75.91	-70.77	-41.23	-37.48
Other Expense / Income	-4.91	-1.18	-1.38	-4.62	-3.75
Pretax Income	-62.72	-74.73	-69.39	-36.6	-33.74
Net Income	-62.72	-74.73	-69.39	-36.6	-33.74
Shares Outstanding (Basic)	28	28	28	28	16
Shares Outstanding (Diluted)	28	28	28	28	16
Shares Change	0.33%	0.46%	0.30%	75.41%	1045.78%
EPS (Basic)	-2.25	-2.69	-2.51	-1.33	-2.15
EPS (Diluted)	-2.25	-2.69	-2.51	-1.33	-2.15
Free Cash Flow	-53.79	-56	-59.64	-52.09	-38.99
Free Cash Flow Per Share	-1.93	-2.02	-2.16	-1.89	-2.48
Gross Margin	-	-	-	100.00%	100.00%
Operating Margin	-	-	-	-184.22%	-590.55%
Profit Margin	-	-	-	-163.57%	-531.54%
Free Cash Flow Margin	-	-	-	-232.76%	-614.37%
EBITDA	-58.47	-70.25	-65.21	-33.19	-31.05
EBITDA Margin	-	-	-	-148.32%	-489.19%
Depreciation & Amortization	4.26	4.48	4.18	3.41	2.69
EBIT	-62.72	-74.73	-69.39	-36.6	-33.74
EBIT Margin	-	-	-	-163.57%	-531.54%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).